Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab
人类 LAG-3 阻断抗体 Relatlimab 单独或与 Nivolumab 联合使用的临床前表征
期刊:Cancer Immunology Research
影响因子:8.1
doi:10.1158/2326-6066.CIR-22-0057
Kent Thudium #, Mark Selby #, Julie A Zorn #, Gregory Rak #, Xi-Tao Wang, Roderick Todd Bunch, Jason M Hogan, Pavel Strop #, Alan J Korman #
